• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    First-Line immune checkpoint inhibition for advanced non-small-cell lung cancer: state of the art and future directions

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Ackermann, Christoph J
    Adderley, H.
    Ortega-Franco, A.
    Khan, A.
    Reck, M.
    Califano, Raffaele
    Affiliation
    Department of Medical Oncology, Spital STS AG, Thun, Switzerland.
    Issue Date
    2020
    
    Metadata
    Show full item record
    Abstract
    The advent of PD-(L)1 and CTLA-4 immune check point inhibitors (CPIs) has dramatically changed the treatment landscape of advanced non-small-cell lung cancer (NSCLC). For up to a quarter of patients with advanced NSCLC, CPIs have the potential to induce durable responses with long-term survival outcomes. Since the approval of first-line pembrolizumab for patients whose tumors express a PD-L1 ? 50%, several pivotal first-line CPI-based phase 3 studies have been conducted investigating combination treatments combining CPIs with chemotherapy (ChT) or combining different CPIs with or without ChT. As a result, there has been an increase in front-line treatment options for advanced NSCLC, and treatment algorithms are changing very quickly. In fit patients with advanced NSCLC, combination treatments including CPI and ChT are considered the new standard of care with improved clinical outcomes. CPI combination treatments are well tolerated and quality of life also seems to be better when CPIs are implemented in the first-line setting. The aim of this review is to provide a summary of the recently published first-line phase 3 studies investigating CPIs as monotherapy or in combination with other CPIs or ChT in advanced NSCLC, and to suggest possible treatment algorithms.
    Citation
    Ackermann CJ, Adderley H, Ortega-Franco A, Khan A, Reck M, Califano R. First-Line Immune Checkpoint Inhibition for Advanced Non-Small-Cell Lung Cancer: State of the Art and Future Directions. Drugs. 2020;80(17):1783-97.
    Journal
    Drugs
    URI
    http://hdl.handle.net/10541/623352
    DOI
    10.1007/s40265-020-01409-6
    PubMed ID
    32986224
    Additional Links
    https://dx.doi.org/10.1007/s40265-020-01409-6
    Type
    Article
    Language
    en
    ae974a485f413a2113503eed53cd6c53
    10.1007/s40265-020-01409-6
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Comparison of Efficacy and Safety of Single and Double Immune Checkpoint Inhibitor-Based First-Line Treatments for Advanced Driver-Gene Wild-Type Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis.
    • Authors: Xu Q, Zhang X, Huang M, Dai X, Gao J, Li S, Sheng L, Huang K, Wang J, Liu L
    • Issue date: 2021
    • Determining the optimal PD-1/PD-L1 inhibitors for the first-line treatment of non-small-cell lung cancer with high-level PD-L1 expression in China.
    • Authors: Teng MM, Chen SY, Yang B, Wang Y, Han RY, An MN, Dong YL, You HS
    • Issue date: 2021 Sep
    • Combination therapy with PD-1 or PD-L1 inhibitors for cancer.
    • Authors: Hayashi H, Nakagawa K
    • Issue date: 2020 May
    • Pan-Cancer Analysis Identifies Liver Metastases as Negative Predictive Factor for Immune Checkpoint Inhibitors Treatment Outcome.
    • Authors: Chen XJ, Ren A, Zheng L, Zheng ED, Jiang T
    • Issue date: 2021
    • Immune Checkpoint Inhibitors for Patients With Advanced Non-Small-Cell Lung Cancer: A Systematic Review.
    • Authors: Ellis PM, Vella ET, Ung YC
    • Issue date: 2017 Sep
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.